12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
Public ClinicalTrials.gov record NCT01370005. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2 diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular complications, assessment of both glucose and blood pressure lowering effects of BI 10773 in hypertensive patients with type 2 diabetes could provide clinically highly relevant, new information for the use of BI 10773
Study identification
- NCT ID
- NCT01370005
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 825 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2011 (Type not available)
- Primary completion
- Jul 2012 (Actual)
- Completion
- Jul 2012 (Actual)
- Last update posted
- Feb 22, 2016
2011 – 2012
United States locations
- U.S. sites
- 35
- U.S. states
- 15
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1245.48.10024 Boehringer Ingelheim Investigational Site | Huntsville | Alabama | — | — |
| 1245.48.10002 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1245.48.10014 Boehringer Ingelheim Investigational Site | Lincoln | California | — | — |
| 1245.48.10030 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 1245.48.10033 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 1245.48.10027 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1245.48.10041 Boehringer Ingelheim Investigational Site | Tustin | California | — | — |
| 1245.48.10039 Boehringer Ingelheim Investigational Site | West Hills | California | — | — |
| 1245.48.10008 Boehringer Ingelheim Investigational Site | Davie | Florida | — | — |
| 1245.48.10025 Boehringer Ingelheim Investigational Site | Edgewater | Florida | — | — |
| 1245.48.10001 Boehringer Ingelheim Investigational Site | Jacksonville | Florida | — | — |
| 1245.48.10016 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1245.48.10035 Boehringer Ingelheim Investigational Site | Palm Harbor | Florida | — | — |
| 1245.48.10018 Boehringer Ingelheim Investigational Site | Pensacola | Florida | — | — |
| 1245.48.10032 Boehringer Ingelheim Investigational Site | Pinellas Park | Florida | — | — |
| 1245.48.10012 Boehringer Ingelheim Investigational Site | Marietta | Georgia | — | — |
| 1245.48.10011 Boehringer Ingelheim Investigational Site | Addison | Illinois | — | — |
| 1245.48.10019 Boehringer Ingelheim Investigational Site | Arlington Heights | Illinois | — | — |
| 1245.48.10022 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1245.48.10017 Boehringer Ingelheim Investigational Site | Wichita | Kansas | — | — |
| 1245.48.10010 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 1245.48.10036 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1245.48.10005 Boehringer Ingelheim Investigational Site | Akron | Ohio | — | — |
| 1245.48.10004 Boehringer Ingelheim Investigational Site | Kettering | Ohio | — | — |
| 1245.48.10013 Boehringer Ingelheim Investigational Site | Erie | Pennsylvania | — | — |
| 1245.48.10020 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1245.48.10029 Boehringer Ingelheim Investigational Site | Knoxville | Tennessee | — | — |
| 1245.48.10015 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 1245.48.10034 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1245.48.10007 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1245.48.10009 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1245.48.10042 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1245.48.10026 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1245.48.10003 Boehringer Ingelheim Investigational Site | Orem | Utah | — | — |
| 1245.48.10023 Boehringer Ingelheim Investigational Site | Port Orchard | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01370005, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 22, 2016 · Synced Nov 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01370005 live on ClinicalTrials.gov.